Trends in Heart Failure Outcomes From a Large, Geographically Diverse Cohort During the COVID-19 PandemicThe evolving coronavirus disease 2019 (COVID-19) pandemic has presented extraordinary challenges to the health of populations globally. As our understanding of the virus continues to grow at a rapid pace, it has become increasingly clear that the clinical manifestations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection range widely and are in large part dictated by age, underlying comorbidities, and vaccination status. Robust epidemiologic data during the past years have underscored that individuals with chronic health conditions including cardiovascular disease, diabetes mellitus, immunosuppression, tobacco use, and obesity carry a significantly greater risk of falling critically ill with SARS-CoV-2.
Understanding Heart Failure Risk in a Diverse Cohort With Human Immunodeficiency Virus InfectionAfter 4 decades of study and numerous therapeutic advancements, human immunodeficiency virus (HIV) infection can today be considered and managed as a chronic disease, and in some parts of the world, the life expectancy of persons living with HIV (PWHs) is comparable to that of persons living without such infection.1 Since it was discovered in the early 1980s, HIV has been known to affect the heart. As PWHs are living longer, their burden of cardiovascular disease (CVD) and their clinical relevance have grown, raising important questions about the pathophysiologic process through which the HIV affects the heart despite optimal treatment with antiretroviral therapy (ART).